FDC Limited (BOM: 531599)
India
· Delayed Price · Currency is INR | Market Cap | 80.82B |
| Revenue (ttm) | 20.72B |
| Net Income (ttm) | 3.17B |
| Shares Out | 162.81M |
| EPS (ttm) | 19.37 |
| PE Ratio | 25.63 |
| Forward PE | n/a |
| Dividend | 10.00 (2.01%) |
| Ex-Dividend Date | Nov 22, 2024 |
| Volume | 5,092 |
| Open | 501.05 |
| Previous Close | 495.95 |
| Day's Range | 492.60 - 503.65 |
| 52-Week Range | 375.65 - 659.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 31, 2024 |
About FDC Limited
FDC Limited manufactures and markets pharmaceutical products in India and internationally. The company offers specialized formulations for various therapeutic segments, including anti-infective, gastrointestinal, ophthalmic, vitamins, minerals, dietary supplements, cardiac, anti-diabetes, respiratory, gynaecology, dermatology, and analgesics; and anti-oxidants, balanced energy and protein drinks, and vitamins and nutraceuticals, as well as various active pharmaceutical ingredients. It provides its products under the Zifi, Zefu, Zocon, Amodep-AT... [Read more]
Financial Performance
In 2023, FDC Limited's revenue was 19.43 billion, an increase of 8.92% compared to the previous year's 17.84 billion. Earnings were 3.05 billion, an increase of 57.30%.
Financial StatementsNews
FDC shares surge 11%, leading gains in BSE Healthcare index
Shares of FDC Limited surged by 11.22% today, reaching ₹642.95, making it one of the top performers in the BSE Healthcare Index. The index itself was up 1.0%, with other top gainers including Hikal Ch...